1 Division of Thoracic Surgery, Dr. Nafiz Korez Sincan State Hospital, Ankara, Turkey ; 2 Department of Pathology, Hacettepe University School of Medicine, Ankara, Turkey ; 3 Department of Pathology, Istanbul University School of Medicine, Istanbul, Turkey ; 4 Department of Thoracic Surgery, Hacettepe University School of Medicine, Ankara, Turkey.
J Thorac Dis. 2014 Jun;6(6):778-84. doi: 10.3978/j.issn.2072-1439.2014.04.35.
The impacts of epidermal growth factor receptor (EGFR) immunoexpression and RAS immunoexpression on the survival and prognosis of lung adenocarcinoma patients are debated in the literature.
Twenty-six patients, who underwent pulmonary resections between 2002 and 2007 in our clinic, and whose pathologic examinations yielded adenocarcinoma, were included in the study. EGFR and RAS expression levels were examined by immunohistochemical methods. The results were compared with the survival, stage of the disease, nodal involvement, lymphovascular invasion, and pleural invasion. Nonparametric bivariate analyses were used for statistical analyses.
A significant link between EGFR immunoexpression and survival has been identified while RAS immunoexpression and survival have been proven to be irrelevant. Neither EGFR, nor RAS has displayed a significant link with the stage of the disease, nodal involvement, lymphovascular invasion, or pleural invasion.
Positive EGFR immunoexpression affects survival negatively, while RAS immunoexpression has no effect on survival in lung adenocarcinoma patients.
表皮生长因子受体（EGFR）免疫表达和 RAS 免疫表达对肺腺癌患者的生存和预后的影响在文献中存在争议。
本研究纳入了 2002 年至 2007 年间在我院接受肺切除术且病理检查为腺癌的 26 例患者。采用免疫组织化学方法检测 EGFR 和 RAS 的表达水平。将结果与生存、疾病分期、淋巴结受累、血管淋巴管侵犯和胸膜侵犯进行比较。采用非参数双变量分析进行统计分析。
EGFR 免疫表达与生存之间存在显著关联，而 RAS 免疫表达与生存无关。EGFR 和 RAS 均与疾病分期、淋巴结受累、血管淋巴管侵犯或胸膜侵犯无显著关联。
肺腺癌患者中，EGFR 免疫表达阳性会对生存产生负面影响，而 RAS 免疫表达对生存无影响。
